BRPI0612254A2 - composto, formulação farmacêutica, combinação, e, processo para preparar um composto - Google Patents
composto, formulação farmacêutica, combinação, e, processo para preparar um compostoInfo
- Publication number
- BRPI0612254A2 BRPI0612254A2 BRPI0612254A BRPI0612254A BRPI0612254A2 BR PI0612254 A2 BRPI0612254 A2 BR PI0612254A2 BR PI0612254 A BRPI0612254 A BR PI0612254A BR PI0612254 A BRPI0612254 A BR PI0612254A BR PI0612254 A2 BRPI0612254 A2 BR PI0612254A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- combination
- pharmaceutical formulation
- formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0501425 | 2005-06-20 | ||
PCT/SE2006/000741 WO2006137782A1 (en) | 2005-06-20 | 2006-06-19 | Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0612254A2 true BRPI0612254A2 (pt) | 2016-09-06 |
Family
ID=37570721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0612254A BRPI0612254A2 (pt) | 2005-06-20 | 2006-06-19 | composto, formulação farmacêutica, combinação, e, processo para preparar um composto |
Country Status (18)
Country | Link |
---|---|
US (1) | US7863265B2 (pt) |
EP (1) | EP1896407A4 (pt) |
JP (1) | JP2008546766A (pt) |
KR (1) | KR20080019710A (pt) |
CN (1) | CN101228123A (pt) |
AR (1) | AR054484A1 (pt) |
AU (1) | AU2006259949A1 (pt) |
BR (1) | BRPI0612254A2 (pt) |
CA (1) | CA2610890A1 (pt) |
EC (1) | ECSP088114A (pt) |
IL (1) | IL187736A0 (pt) |
MX (1) | MX2007016483A (pt) |
NO (1) | NO20076137L (pt) |
RU (1) | RU2007147338A (pt) |
TW (1) | TW200730493A (pt) |
UY (1) | UY29607A1 (pt) |
WO (1) | WO2006137782A1 (pt) |
ZA (1) | ZA200710415B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA04250427A (ar) | 2003-12-23 | 2005-12-03 | استرازينيكا ايه بي | مشتقات ثاني فينيل أزيتيدون |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
MY148538A (en) * | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US9212175B2 (en) | 2009-03-06 | 2015-12-15 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
CZ309209B6 (cs) | 2001-01-26 | 2022-05-25 | Schering Corporation | Farmaceutický prostředek |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
SI1427409T1 (sl) | 2001-09-21 | 2009-02-28 | Schering Corp | Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US6761509B2 (en) | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
US6960047B2 (en) | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
CA2504878A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
MXPA05009503A (es) * | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
EP1626954A2 (en) | 2003-05-05 | 2006-02-22 | Ranbaxy Laboratories, Ltd. | Process for the preparation of trans-isomers of diphenylazetidinone derivatives |
US20040259179A1 (en) | 2003-05-30 | 2004-12-23 | Gerd Assmann | Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US7002008B2 (en) | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
WO2005021495A2 (en) | 2003-08-25 | 2005-03-10 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
WO2005021497A2 (en) | 2003-08-28 | 2005-03-10 | Microbia, Inc. | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones |
EP1522541A1 (en) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
JP2007509963A (ja) | 2003-10-30 | 2007-04-19 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血漿薬としての2−アゼチジノン |
WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
EP1680189A2 (en) | 2003-11-05 | 2006-07-19 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
PL1682499T3 (pl) | 2003-11-10 | 2008-01-31 | Microbia Inc | 4-Biarylilo-1-fenyloazetydyn-2-ony |
EP1687287A1 (en) | 2003-11-24 | 2006-08-09 | Hetero Drugs Limited | A novel process for ezetimibe intermediate |
KR20060118557A (ko) | 2003-12-17 | 2006-11-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 의약 조성물 및 조합물 |
GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
EP1699760B1 (en) | 2003-12-23 | 2017-05-17 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
US20050171080A1 (en) | 2003-12-23 | 2005-08-04 | Dr. Reddy's Laboratories, Inc. | Polymorphs of ezetimibe and process for preparation thereof |
SA04250427A (ar) * | 2003-12-23 | 2005-12-03 | استرازينيكا ايه بي | مشتقات ثاني فينيل أزيتيدون |
WO2005066120A2 (en) | 2003-12-30 | 2005-07-21 | Ranbaxy Laboratories Limited | Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives |
US7901893B2 (en) | 2004-01-16 | 2011-03-08 | Merck Sharp & Dohme Corp. | NPC1L1 (NPC3) and methods of identifying ligands thereof |
WO2005067903A1 (en) | 2004-01-20 | 2005-07-28 | Panacea Biotec Ltd. | Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
KR100725758B1 (ko) * | 2004-03-30 | 2007-06-08 | 삼성광주전자 주식회사 | 전동 송풍기 및 이를 이용한 자동차용 전동 과급기 |
DE502005001841D1 (de) | 2004-05-21 | 2007-12-13 | Sanofi Aventis Deutschland | Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten |
DE102004025072A1 (de) | 2004-05-21 | 2005-12-15 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten |
WO2006017257A2 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Azetidinone derivatives |
US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
CA2581596A1 (en) | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
WO2006060808A1 (en) | 2004-12-03 | 2006-06-08 | Teva Pharmaceutical Industries Ltd. | Ezetimibe polymorphs |
SG158132A1 (en) | 2004-12-20 | 2010-01-29 | Schering Corp | Process for the synthesis of azetidinones |
IL166149A0 (en) | 2005-01-05 | 2006-01-15 | Hadasit Med Res Service | Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity |
EP1851197A2 (en) | 2005-02-09 | 2007-11-07 | Microbia, Inc. | Phenylazetidinone derivatives |
US20090186834A1 (en) | 2005-03-24 | 2009-07-23 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
US8361999B2 (en) | 2005-04-04 | 2013-01-29 | Pontificia Universidad Catolica De Chile | Methods of treating cholesterol gallstone disease with ezetimibe |
US20080194494A1 (en) | 2005-04-26 | 2008-08-14 | Microbia, Inc. | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia |
WO2006121861A2 (en) | 2005-05-05 | 2006-11-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
WO2006122186A2 (en) | 2005-05-10 | 2006-11-16 | Microbia, Inc. | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
CN101218213A (zh) | 2005-05-11 | 2008-07-09 | 迈克罗比亚公司 | 制备酚类4-联苯基氮杂环丁烷-2-酮的方法 |
EP1885694A2 (en) | 2005-05-13 | 2008-02-13 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
BRPI0611415A2 (pt) | 2005-05-25 | 2010-09-08 | Microbia Inc | ácidos fosfÈnicos de 4-(bifenilil)azetidin-2-ona e processo para a produção dos mesmos |
WO2006134604A1 (en) | 2005-06-15 | 2006-12-21 | Hetero Drugs Limited | Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor |
WO2006138163A2 (en) | 2005-06-15 | 2006-12-28 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
MY148538A (en) | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR056866A1 (es) * | 2005-06-22 | 2007-10-31 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto |
RU2008102236A (ru) | 2005-06-22 | 2009-07-27 | РЕДДИ Манне САТЬЯНАРАЯНА (IN) | Улучшенный способ получения эзетимиб |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
AR057383A1 (es) | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
EP1741427A1 (en) | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
WO2007008529A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc | Celullar cholesterol absorption modifiers |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
EP1912937A1 (en) | 2005-08-01 | 2008-04-23 | Warner-Lambert Company LLC | Novel substituted azetidinones |
US20100119525A1 (en) | 2005-08-01 | 2010-05-13 | Mount Sinai Schoool Of Medicine Of New York University | Method for extending longevity using npc1l1 antagonists |
WO2007017705A1 (en) | 2005-08-09 | 2007-02-15 | Glenmark Pharmaceuticals Limited | Process for the preparation of azetidinones |
US20070049748A1 (en) | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
WO2007030721A2 (en) | 2005-09-08 | 2007-03-15 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
TW200806623A (en) | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
PE20070824A1 (es) | 2005-11-15 | 2007-08-24 | Takeda Pharmaceutical | Composicion farmaceutica que contiene lapaquistat y ezetimibe en el tratamiento de hiperlipidemia |
DE102005055726A1 (de) | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US7498431B2 (en) | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
HU0501164D0 (en) | 2005-12-20 | 2006-02-28 | Richter Gedeon Vegyeszet | New industrial process for the production of ezetimibe |
JP2009521452A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | コレステロール降下剤およびh3受容体アンタゴニスト/逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置 |
TW200811098A (en) * | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
MX2009002924A (es) * | 2006-09-15 | 2009-05-28 | Schering Corp | Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos. |
PE20081877A1 (es) * | 2007-03-06 | 2008-12-27 | Teijin Pharma Ltd | Derivado de la 1,4-diarilacetidinona |
-
2006
- 2006-06-16 UY UY29607A patent/UY29607A1/es unknown
- 2006-06-19 US US11/993,033 patent/US7863265B2/en not_active Expired - Fee Related
- 2006-06-19 RU RU2007147338/04A patent/RU2007147338A/ru not_active Application Discontinuation
- 2006-06-19 JP JP2008518077A patent/JP2008546766A/ja active Pending
- 2006-06-19 EP EP06747933A patent/EP1896407A4/en not_active Withdrawn
- 2006-06-19 KR KR1020087001031A patent/KR20080019710A/ko not_active Application Discontinuation
- 2006-06-19 WO PCT/SE2006/000741 patent/WO2006137782A1/en active Application Filing
- 2006-06-19 AU AU2006259949A patent/AU2006259949A1/en not_active Abandoned
- 2006-06-19 CN CNA2006800264766A patent/CN101228123A/zh active Pending
- 2006-06-19 BR BRPI0612254A patent/BRPI0612254A2/pt not_active IP Right Cessation
- 2006-06-19 CA CA002610890A patent/CA2610890A1/en not_active Abandoned
- 2006-06-19 MX MX2007016483A patent/MX2007016483A/es not_active Application Discontinuation
- 2006-06-20 TW TW095122114A patent/TW200730493A/zh unknown
- 2006-06-20 AR ARP060102624A patent/AR054484A1/es unknown
-
2007
- 2007-11-28 IL IL187736A patent/IL187736A0/en unknown
- 2007-11-28 NO NO20076137A patent/NO20076137L/no not_active Application Discontinuation
- 2007-11-30 ZA ZA200710415A patent/ZA200710415B/xx unknown
-
2008
- 2008-01-17 EC EC2008008114A patent/ECSP088114A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US7863265B2 (en) | 2011-01-04 |
CA2610890A1 (en) | 2006-12-28 |
RU2007147338A (ru) | 2009-07-27 |
JP2008546766A (ja) | 2008-12-25 |
EP1896407A4 (en) | 2010-06-16 |
ZA200710415B (en) | 2008-10-29 |
UY29607A1 (es) | 2007-01-31 |
NO20076137L (no) | 2008-01-18 |
KR20080019710A (ko) | 2008-03-04 |
EP1896407A1 (en) | 2008-03-12 |
AR054484A1 (es) | 2007-06-27 |
MX2007016483A (es) | 2008-03-10 |
AU2006259949A1 (en) | 2006-12-28 |
IL187736A0 (en) | 2008-08-07 |
CN101228123A (zh) | 2008-07-23 |
TW200730493A (en) | 2007-08-16 |
ECSP088114A (es) | 2008-02-20 |
US20100216759A1 (en) | 2010-08-26 |
WO2006137782A1 (en) | 2006-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0612254A2 (pt) | composto, formulação farmacêutica, combinação, e, processo para preparar um composto | |
BRPI0611956A2 (pt) | composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto | |
BRPI0821676A2 (pt) | Composto, composição farmacêutica, e, processo para a preparação dos compostos. | |
BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. | |
BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
BRPI0807807A2 (pt) | " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ". | |
BRPI0607423A2 (pt) | forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto | |
BRPI0812054A2 (pt) | Processo para preparar compostos, e, compostos. | |
BRPI0814611A2 (pt) | Composição, processo para preparar uma composição, e, uso de uma composição | |
BRPI0909354A2 (pt) | processo para a produção de microcápsulas, microcápsula, formulação agroquímica, e, uso da mesma. | |
BRPI0909691A8 (pt) | composto, método para preparar um composto, e, composição farmacêutica | |
BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
BRPI0720530A2 (pt) | Partícula, processo para preparar a partícular, e, composição | |
BRPI0815493A2 (pt) | Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto. | |
BRPI0815784A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
BRPI0813772A2 (pt) | Composto, processo para a preparação de um composto, e, conjugado | |
BRPI0911897A2 (pt) | Processo para a preparação de compostos, e, composto | |
BRPI0811275A2 (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença | |
BRPI0614608A2 (pt) | análogos de camptotecina, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os ditos compostos | |
BRPI1016109A2 (pt) | "composto, composição farmacêutica, e, processo para preparar um composto" | |
BRPI0719706A2 (pt) | Processo para a preparação do 1,3-propanodiol. | |
BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRANSLADO OU FOTOCOPIA AUTENTICADA. |
|
B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 020070179894/RJ DE 18/12/2007. |
|
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.13 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
B11O | Dismissal: republication [chapter 11.15 patent gazette] |
Free format text: RETIFICACAO DO DESPACHO 11.13, QUE FOI PUBLICADO NA RPI 2382. O CORRETO SERIA, ANULACAO DO DESPACHO 11.6.1, NO TEXTO DO DESPACHO OCORRIDO. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |